（记者 王晓波） 每经AI快讯，三星医疗12月30日晚间发布公告称，公司第六届董事会第二十七次会议于2025年12月30 日在公司会议室以现场及通讯方式召开。会议审议了《关于2026年度预计日常关联交易的议案》等文 件。 每经头条（nbdtoutiao）——2025十大财经新闻出炉！护航、酣战、变局、狂飙分别指向哪些大事件？ ...

证券代码：601567 证券简称：三星医疗 公告编号：临 2025-099 宁波三星医疗电气股份有限公司 关于 2026 年度预计日常关联交易的公告 （一）日常关联交易履行的审议程序 宁波三星医疗电气股份有限公司（以下简称"公司"）于2025年12月30日召开公 司第六届董事会第二十七次会议，审议通过了《关于2026年度预计日常关联交易的 议案》，其中关联董事已回避表决，该议案已经独立董事专门会议审议通过。 （二）2025年度日常关联交易的执行情况 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示: ● 2026年度日常关联交易无需提交股东大会审议。 ● 关联交易完成后对上市公司的影响：2026年预计发生的日常关联交易系与公 司日常经营相关的关联交易，符合公司生产经营的实际需求。交易价格以市场价格 为基础协商定价，公平合理，对本公司持续经营能力、盈利能力及资产独立性等不 会产生不利影响。此交易不会影响本公司的独立性，公司主要业务不会因此对关联 方形成依赖。 单位：万元 | | | | | 预计金额 | | | -- ...

该议案已经公司独立董事专门会议审议通过。 宁波三星医疗电气股份有限公司（以下简称"公司"）于 2025 年 12 月 25 日以电话、传真、邮件等方式发出召开第六届董事会第二十七次会议的通知，会 议于 2025 年 12 月 30 日在公司会议室以现场及通讯方式召开。会议应到董事 9 人，实到董事 9 人，会议由董事长沈国英女士主持，公司其他高级管理人员列席 了会议，会议的召集和召开符合《公司法》和《公司章程》的有关规定。经与会 董事认真审议并表决，通过了以下议案，形成决议如下： 一、审议通过了关于 2026 年度预计日常关联交易的议案 详见公司披露于上海证券交易所网站（www.sse.com.cn）的《三星医疗关于 2026 年度预计日常关联交易的公告》（公告编号：临 2025-099）。 表决结果：6 票赞成、0 票反对、0 票弃权，3 票回避，关联董事沈国英、郑 坚江、吕萌回避表决。 证券代码：601567 证券简称：三星医疗 公告编号：临 2025-098 宁波三星医疗电气股份有限公司 第六届董事会第二十七次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏 ...

证券代码：601567 证券简称：三星医疗 公告编号：临2025-097 宁波三星医疗电气股份有限公司 关于为子公司提供担保的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 累计担保情况 | 对外担保逾期的累计金额（万元） | 0 | | --- | --- | | 截至本公告日上市公司及其控股 子公司对外担保总额（万元） | 975,350.00 | | 对外担保总额占上市公司最近一 期经审计净资产的比例（%） | 80.73% | | 100% 特别风险提示（如有请勾选） | □对外担保总额超过最近一期经审计净资产 担保金额超过上市公司最近一期经审计净 | | 资产 | 50% | | | □对合并报表外单位担保金额达到或超过最 | | | 近一期经审计净资产 30%的情况下 | | | 对资产负债率超过 70%的单位提供担保 | | 其他风险提示（如有） 无 | | 注：表中截至本公告日上市公司及其控股子公司对外担保总额，包含年度已批准的担 保额度内尚未使用额度与担保实际发生余额之和，并非公 ...

三星医疗公告称，近日与浦发银行签订《最高额保证合同》，为全资子公司奥克斯智能科技提供1亿元 银行授信担保，期限自2025年12月26日至2030年12月26日。截至公告披露日，公司对其实际担保余额达 44.63亿元（含本次）。公司及控股子公司对外担保总额97.54亿元，占2024年度经审计净资产的 80.73%，无逾期担保。该担保事项已履行必要审批程序，总体风险可控。 ...

Group 1 - The high-pressure oxygen chamber concept declined by 0.92%, ranking among the top declines in the concept sector, with companies like Innovation Medical, Aoyang Health, and Yinkang Life experiencing significant drops [1] - Among the concept stocks, Jinling Pharmaceutical, Tiedao Heavy Industry, and Hangyang Co. saw increases of 2.93%, 0.77%, and 0.26% respectively [1] - The top-performing concept sectors today included Hainan Free Trade Zone with a rise of 4.32%, and various metal sectors such as zinc and lead, which increased by 3.61% and 3.30% respectively [1] Group 2 - The high-pressure oxygen chamber concept experienced a net outflow of 199 million yuan, with six stocks seeing significant outflows, led by Innovation Medical with a net outflow of 132 million yuan [1] - Other companies with notable net outflows included Hangyang Co. and Yinkang Life, with outflows of 39.31 million yuan and 12.35 million yuan respectively [1] - Conversely, Aoyang Health, Jinling Pharmaceutical, and Dahu Co. were among the stocks with net inflows, receiving 2.49 million yuan, 2.04 million yuan, and 0.47 million yuan respectively [1]

Core Viewpoint - The company is focusing on its "globalization and new energy" strategy, with ongoing developments in overseas markets and new energy business segments [1] Group 1: New Energy Strategy - The company’s new energy products include photovoltaic transformers, charging piles, inverters, and energy storage solutions [1] - The photovoltaic transformer has received domestic first-set certification, while the charging pile business secured its first European order in Sweden worth 124 million yuan [1] - The inverter business has made continuous breakthroughs in the Brazilian market, and energy storage products include low-voltage home storage solutions ranging from 5-16 kWh and high-voltage stacked battery packs [1] Group 2: Order Status - As of the end of Q3 2025, the company has a total order backlog of 17.914 billion yuan, representing a year-on-year increase of 14.69% [1] - The overseas distribution order backlog stands at 2.169 billion yuan, showing a significant year-on-year growth of 125.45% [1] Group 3: Product Development - The company is developing intelligent management platforms that integrate self-developed Battery Management Systems (BMS) and Energy Management Systems (EMS), along with AI diagnostics to enhance operational efficiency and energy generation [1]

Core Viewpoint - Samsung Medical (601567) has signed a contract for a smart meter project in Brazil, which is expected to contribute to its revenue in 2024 [1] Group 1: Company Performance - As of December 24, 2025, Samsung Medical's stock closed at 23.16 yuan, reflecting a 0.09% increase from the previous trading day [1] - The company's total market capitalization is 32.545 billion yuan [1] - The stock opened at 23.01 yuan, reached a high of 23.43 yuan, and a low of 22.91 yuan, with a trading volume of 3.29 billion yuan and a turnover rate of 1.01% [1] Group 2: Contract Details - Samsung Medical's wholly-owned subsidiary, Brazil Nansen, has signed a contract with CPFL ENERGIA for the Brazil CPFL smart meter project [1] - The total contract amount is 10,590.99 million Brazilian Reais, approximately 135 million yuan [1] - This contract represents 0.92% of the company's audited operating revenue for the year 2024 [1] Group 3: Risks - The announcement highlights potential risks during the contract execution, including force majeure, adjustments in international trade policies, and exchange rate fluctuations [1]

Group 1 - Samsung Medical announced that its wholly-owned subsidiary, Brazil Nansen, signed a contract for the Brazil CPFL smart meter project valued at 105.9099 million Brazilian Reais, approximately 135 million RMB, which accounts for 0.92% of the company's revenue in 2024 [1] - The company stated that this contract will have a positive impact on its operating performance [1]

Group 1 - Jizhi Co., Ltd. plans to acquire at least 51% equity in Pumai Technology through cash payment, aiming to gain control over the company, which is a leading enterprise in the field of robot performance testing and calibration in China [1] - Yaxing Chemical's subsidiary intends to transfer 7.14% equity for 60 million yuan to another fund under the same control, indicating strategic investment movements within the same management group [2] - Weigao Bio's application for clinical trials of subcutaneous human immunoglobulin has been accepted by the National Medical Products Administration, targeting primary immunodeficiency diseases [3] Group 2 - Sentai Co., Ltd.'s controlling shareholder plans to increase shareholding by at least 100 million yuan within 12 months, aiming to enhance confidence in the company's future [4] - Health元's subsidiary has received acceptance for the marketing authorization application of Lecanemab injection, which is intended for moderate to severe plaque psoriasis patients [5][11] - Sunshine Nuohuo has signed a technical development contract for the STC008 injection project, with a total payment of 500 million yuan, indicating significant investment in cancer treatment [6] Group 3 - Hunan YN has been designated as a delivery warehouse for lithium carbonate by the Guangzhou Futures Exchange, enhancing its position in the lithium market [7] - Tianji Co., Ltd. is pushing for the industrialization of lithium sulfide material preparation, although it faces risks in commercialization [8] - Yuandong Bio has received FDA approval for Methylene Blue injection, expanding its product portfolio in the U.S. market [10] Group 4 - Nanshan Aluminum has established a wholly-owned subsidiary in Hainan with an investment of 5 million yuan, focusing on high-end aluminum products [13] - ST Xifa plans to acquire 50% equity in Lhasa Beer, aiming for full ownership, with the transaction currently in the planning stage [14] - Hengrui Medicine's SHR-A1904 injection has been included in the list of breakthrough therapy products, indicating its potential in treating advanced gastric cancer [12] Group 5 - Chengdu Gas is planning to merge three subsidiaries, streamlining operations and enhancing efficiency [26] - Baoli Electric intends to invest 50 million yuan to establish a wholly-owned subsidiary focused on key equipment and solutions in energy storage [27] - Huadian International has successfully put the second unit of its Longkou Phase IV project into commercial operation, marking a significant milestone in its energy production capacity [34]